Reta Lila Weston Institute of Neurological Studies, University College London, 1 Wakefield Street, London WC1N 1PJ, UK.
Brain. 2010 Jun;133(Pt 6):1755-62. doi: 10.1093/brain/awq059. Epub 2010 Apr 5.
To investigate the relationships between age, the advanced clinical stages of Parkinson's disease and neuropathology, we surveyed 129 case records from donors with pathologically proven Parkinson's disease at the Queen Square Brain Bank for Neurological Disorders. Cases were separated into five groups according to age at death, thus comparing patients who reached the advanced stage of the disease at different ages. Four milestones of advanced disease (frequent falls, visual hallucinations, dementia and need for residential care) occurred at a similar time from death in each group. There were no significant differences in disease duration across these age groupings, nor were there differences in the severity and distribution of Lewy body and other pathologies. The milestones of dementia (P < 0.0005) and visual hallucinations (P = 0.02) as well as the accumulation of multiple milestones (P < 0.0005) were associated with high cortical Lewy body scores. Demented cases also had significantly more Alzheimer neurofibrillary and amyloid-beta plaque pathology. Correlation analysis showed that the time intervals between disease onset and recording of milestones were strongly influenced by age at onset (P < 0.0001) and by total disease duration (P < 0.0001). The advanced disease phase plays out in a similar fashion at whatever age it occurs, with a common pathological endpoint. The clinico-pathological comparisons for the final stage of Parkinson's disease do support a staging system based on the rostral extent and severity of Lewy body pathology, although other pathologies may play a synergistic role in causing cognitive disability. The chief effects of age on the rate of progression are seen over the early-middle part of the disease. An exponential curve for clinical progression provides the best explanation for these observations about age and the disease course.
为了研究年龄、帕金森病的晚期临床阶段和神经病理学之间的关系,我们调查了来自 Queen Square 神经疾病大脑银行的 129 例经病理证实的帕金森病患者的病例记录。这些病例根据死亡时的年龄分为五组,从而比较了在不同年龄达到疾病晚期的患者。四个晚期疾病的里程碑(频繁跌倒、视觉幻觉、痴呆和需要居住护理)在每组从死亡开始的时间相似。这些年龄组之间的疾病持续时间没有显著差异,Lewy 体和其他病理学的严重程度和分布也没有差异。痴呆的里程碑(P < 0.0005)和视觉幻觉(P = 0.02)以及多个里程碑的积累(P < 0.0005)与皮质 Lewy 体评分较高有关。痴呆病例的阿尔茨海默神经纤维和淀粉样蛋白-β斑块病理学也明显更多。相关分析表明,疾病发作和里程碑记录之间的时间间隔受到发病年龄(P < 0.0001)和总疾病持续时间(P < 0.0001)的强烈影响。无论发生在什么年龄,晚期疾病阶段都会以相似的方式发展,达到共同的病理终点。帕金森病最后阶段的临床病理比较确实支持基于 Lewy 体病理学的头侧范围和严重程度的分期系统,尽管其他病理学可能在导致认知障碍方面发挥协同作用。年龄对进展速度的主要影响在疾病的早期-中期部分可见。临床进展的指数曲线为这些关于年龄和疾病过程的观察结果提供了最佳解释。